Article Text

This article has a correction. Please see:

PDF

Bilateral facial nerve palsy associated with p-ANCA positive vasculitis in a patient with rheumatoid arthritis
  1. OWEN G STEWART,
  2. IAN G SIMMONS,
  3. MIKE F R MARTIN,
  4. ANDREW J MORRELL
  1. Department of Ophthalmology, Leeds General Infirmary, Clarendon Wing, Leeds LS2 9NS, UK
  1. Mr Stewart owenstewart{at}fsmail.net

Statistics from Altmetric.com

Editor,—Rheumatoid arthritis is a chronic, generalised, symmetrical, inflammatory polyarthritis. Extra-articular associations may involve the eyes, heart, lung, skin, and more rarely, the central and peripheral nervous system. We describe a case of bilateral facial paresis associated with a p-ANCA positive vasculitis in a patient with rheumatoid arthritis.

CASE REPORT

A 67 year old woman presented with 2 days of left sided facial weakness. She was known to suffer from rheumatoid arthritis, and displayed the characteristic hand and finger deformities of this condition. Additional features of vitiligo, hypothyroidism, and splenomegaly were present. Her medication consisted of methotrexate 5 mg weekly, thyroxine 100 μg once daily, and folic acid 5 mg once daily. Examination revealed isolated left sided lower motor neuron facial nerve paresis, and a left Bell's palsy was diagnosed. One week later, she returned with right sided facial weakness. No improvement on the left side had occurred and bilateral lower lid paralytic ectropion was evident. A provisional diagnosis of rheumatoid associated mononeuritis multiplex was made, and a rheumatology consultation was obtained. Haematological investigations revealed a positive rheumatoid factor (RF) and p-ANCA, and a raised plasma viscosity of 1.80. Other autoimmune studies including ANA, anti-Ro and La antibodies, and c-ANCA were negative, and renal function was normal. Chest radiography and magnetic resonance imaging of the brain were unremarkable.

Three pulses of intravenous methylprednisolone 500 mg were given over 3 days, with commencement of oral prednisolone 1 mg/kg. Despite intensive topical lubrication, developing exposure keratopathy necessitated the surgical correction of the bilateral paralytic ectropion. The oral prednisolone was rapidly tapered down to 5 mg/day, and then discontinued after 3 months. p-ANCA levels subsequently became undetectable.

Full orbicularis function gradually recovered, but only partial recovery of the lower facial muscles occurred. Renal function remained normal throughout and there was no significant exacerbation of the polyarthritis.

COMMENT

Facial nerve weakness may be the result of a number of underlying disorders including vasculitis. The development of bilateral signs in rapid succession, in association with rheumatoid arthritis, highlighted a potential vasculitic process in this case. Other causes of bilateral weakness such as pontine disease—for example, demyelination, or primary muscular disorders—for example, myasthenia gravis, and post-infective polyneuropathy were excluded on clinical grounds and after investigation.

Rheumatoid factor consists of IgM antibodies against the patients' own IgG, and is an important diagnostic feature in rheumatoid arthritis. However, RF may also be seen in polyarteritis nodosa, scleroderma, Wegener's granulomatosis, systemic lupus erythematosis, and sarcoidosis. No clinical or other investigative features of these conditions were demonstrated in the case described here, and the patient displayed typical erosive joint features of rheumatoid arthritis. RF may lead to immune complex (IC) mediated vasculitis due to IC formation and deposition in the joints and vessels causing endothelial damage, perivascular cellular infiltration, and thrombus formation.1

Another mechanism of a vasculitic process is through leucocyte mediated cytotoxicity caused by ANCA. ANCA may promote neutrophil activation and endothelial injury,2-4 by targeting the neutrophil granule enzymes protease 3 (c-ANCA) and myeloperoxidase (p-ANCA). ANCA are useful diagnostic serological markers in a number of vasculitic conditions such as Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome. They may be found less commonly in rheumatoid arthritis, systemic lupus erythematosis,5inflammatory bowel disease, and autoimmune hepatobiliary diseases.6 In one study, the incidence of p-ANCA in patients with rheumatoid arthritis was 21%, and was strongly associated with nephropathy, more severe disease, and increased inflammation.7

In this case, other conditions more commonly associated with positive ANCA titres were excluded on clinical grounds and following investigation. Magnetic resonance imaging is sensitive for cerebral vasculitis,8 and excluded CNS involvement.

The optimum treatment of ANCA associated vasculitis is generally considered to consist of a combination of corticosteroids and other immunosuppressive agents. Methotrexate, cyclosporin, azathioprine, or cyclophosphamide may be used although the most effective treatment protocols are yet to be determined. Evidence of renal or CNS involvement should prompt aggressive therapy because of potentially life threatening complications. In this case, therapy consisted of pulsed intravenous methylprednisolone in the initial phase, followed by oral prednisolone. Additional immunosuppression was not required as widespread evidence of disease activity was absent. Gradual improvement of the facial paresis occurred and vigorous treatment of the exposure keratopathy prevented visual loss in this case.

Bilateral facial nerve palsy is rarely seen in vasculitic conditions. Isolated reports of bilateral facial nerve paralysis associated with Sjøgren's syndrome9 and polyarteritis nodosa10 exist.

Rheumatoid arthritis is a common condition, and life threatening complications, although rare, are well recognised. Initial presentation may be to the ophthalmologist and awareness of such situations, will improve the prognosis for these patients.

References

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.